Efficacy of ADW S-100 Ionized Water Nasal Spray in Decreasing SARS-Cov-2 Viral Load.
Efficacy of ADW S-100 Ionized Water Nasal Spray in Decreasing SARS-Cov-2 Viral Load in Adults With High Viral Excretion by Nasopharyngeal Swabbing. Randomized, Double-blind, Placebo-controlled, Parallel Group Study.
A nasal spray based on Advanced Water S-100 ionized water would clean the nasal cavity, reduce the viscosity of the mucus and facilitate its elimination and the decongestion of the nose and the prevention of the seizure of the SARS-COV-2 to the epithelial cells of the nasal cavity In fact, a nasal spray based on Advanced Water S-100 ionized water would modify the electrostatic environment of all interactions ensuring this seizure. The negative ions (OH-) contained in Advanced Water S-100 compete with the negative ions of the heparan sulfate, which will destabilize this essential bond for the virus to enter the host cell. In addition, positively charged basic amino acids, in the presence of the basic pH of ADW S-100, will be neutralized by OH- ions which will prevent the formation of salt and hydrogen bridges mediating the formation of the protein S/ACE2 complex. The destabilization of all bonds governing the protein S/ACE2 association process will prevent the virus from entering cells and replicating.
The aim of this study is to evaluate whether the use of ADW S-100 ionized water nasal spray reduces the salivary and nasopharyngeal viral load during an 8-day follow-up of persons recently infected with SARS-Cov-2, and thus potentially decreases the risk of contamination of the entourage.
研究概览
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Aix-en-Provence、法国、13100
- Dr Bouvier's Office
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Men and women ≥ 18 years old
- Informed consent
- Beneficiaries of a social security plan
Vaccinated or unvaccinated against SARS-COV-2:
- Vaccinated individuals have had a 3rd dose for at least one month, or have been infected with SARS-Cov-2 and have had 2 doses of vaccine for at least one month
- Unvaccinated persons are naïve to previous SARS Cov 2 infection
- Positive nasopharyngeal RT-PCR test for selection with a Ct viral load ≤ 23
- Have a phone and internet connection to access the entry application
Exclusion Criteria:
- The participant is related to any member of the study staff or has a close relationship or conflict of interest with the sponsor.
- Known hypersensitivity or allergy to any component of the test product.
- Contraindication to nasal spray
Insufficient vaccination: any incomplete vaccination schedule
- either a 3rd dose within the last month
- or SARS-Cov-2 infection with less than 2 vaccine doses or with 2 vaccine doses less than 1 month old.
- Any condition, including COVID, that is likely to result in hospitalization during study participation.
- Conditions that may result in hospitalization during study participation.
- Known pregnancy or positive urine pregnancy test at D0 by the nurse, or current breastfeeding
- Participation in an antiviral clinical trial or other trial using a medical device for disease prevention COVID 19
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Advanced Water S-100 ionized nasal spray
2 sprays in each nostril, 6 times a day during 8 days
|
2 sprays in each nostril, 6 times a day
|
安慰剂比较:Nasal spray with purified water
2 sprays in each nostril, 6 times a day during 8 days
|
2 sprays in each nostril, 6 times a day
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
To determine whether, compared to placebo, ADW S-100 ionized water administered as a nasal spray more rapidly negatively affects the viral load of individuals infected with SARS-CoV-2
大体时间:8 days
|
% of participants negative at D4 (Ct≥35)
|
8 days
|
合作者和调查者
赞助
合作者
调查人员
- 首席研究员:Christophe Bouvier, Dr、independent oto rhino laryngologist
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 2021-A01861-40
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
SARS-CoV-2 感染的临床试验
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and Prevention尚未招聘
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological Pharmaceutical Co...尚未招聘
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College主动,不招人
-
AIM Vaccine Co., Ltd.Hunan Provincial Center for Disease Control and Prevention完全的
-
Peking UniversityCenters for Disease Control and Prevention, China; Beijing Pinggu District Hospital; Peking University...完全的
-
University Hospital, Montpelliersociete SkillCell - 97198 Jarry; CNRS Alcediag UMR9005 - societe Sys2Diag - 34184 Montpellier完全的
nasal spray的临床试验
-
Stephenson Eye Associates招聘中
-
Medical University of South Carolina完全的